Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580525 | 0.86 | — | — | |
| SCHEMBL17376267 | 0.84 | — | — | |
| SCHEMBL1476914 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL14720581 | 0.73 | — | — | |
| SCHEMBL1477516 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL16145772 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL5159 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL580526 | 0.71 | — | — | |
| SCHEMBL7600171 | 0.68 | — | — | |
| SCHEMBL17080879 | 0.68 | PNMT (0.32) | PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | claimed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| US-20220287748-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | REBORNA BIOSCIENCES, INC. (JP) | 2022-09-15 | — | — | US | claimed |
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-03-01 | — | — | US | claimed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| EP-3816160-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | Reborna Biosciences, Inc. (JP) | 2021-05-05 | — | — | EP | claimed |
| CN-112469707-A | Prophylactic or therapeutic agent for spinal muscular atrophy | 利伯纳生物科学株式会社 | 2021-03-09 | — | — | CN | claimed |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | claimed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-112469707-B | Preventive or therapeutic agent for spinal muscular atrophy | 利伯纳生物科学株式会社 | 2024-06-21 | — | — | CN | disclosed |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240166643-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2024-05-23 | — | — | US | disclosed |
| CN-103347874-A | Dimeric iap inhibitors | NOVARTIS AG | 2013-10-09 | — | — | CN | disclosed |
| CN-103261186-A | Dimeric IAP inhibitors | NOVARTIS AG | 2013-08-21 | — | — | CN | disclosed |
| WO-2013009564-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | SMN1; SMN2, HDAC5, PUM1 | PNMT 2240/4885CHRNB2 1505/4885CHRNB4 1854/4885 |
| US-11999727-B2 | Compounds and methods of use | F12, C1R, ABCG2 | PNMT 2568/4885CHRNB2 3217/4885CHRNB4 3299/4885 |
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | PNMT 637/4885CHRNB2 55/4885CHRNB4 57/4885 |
| US-20240166643-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | ABL1, TPMT, IDH2 | PNMT 79/4885CHRNB2 1797/4885CHRNB4 2263/4885 |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | PNMT 637/4885CHRNB2 55/4885CHRNB4 57/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PNMT 2568/4885CHRNB2 3217/4885CHRNB4 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.